 |
0 Diseases |  |
643 Trials |
|
643 Trials |  |
26774 News |  |
| «12...495496497498499500501502503504505...507508» |
- INGN 225 / Lumos Pharma
Enrollment change: Neoadjuvant/Adjuvant Chemotherapy, Vaccine & Adjuvant Radiation Therapy in p53-Overexpressing Stage III Breast Cancer (clinicaltrials.gov) - May 13, 2013
P1/2, N=24, Active, not recruiting, Sponsor: University of Nebraska
N=50 --> 24
- Rituxan (rituximab) / Roche
New P2 trial: Rituximab-HyperCVAD (R-HCVAD) Alternating With Rituximab-Methotrexate-Cytarabine- (R-MC) in Newly Diagnosed Patients With Diffuse Large B-Cell Lymphoma With MYC-Rearrangement. (clinicaltrials.gov) - May 13, 2013
P2, N=0, Withdrawn, Sponsor: The University of Texas Health Science Center at San Antonio
- cisplatin / Generic mfg., doxorubicin hydrochloride / Generic mfg.
New P2 trial: Intraperitoneal Aerosol Chemotherapy in Gastric Cancer (clinicaltrials.gov) - May 13, 2013
P2, N=50, Recruiting, Sponsor: Ruhr University of Bochum
- Trial termination: IROCHIM: Evaluation of Chemotherapy Influence on Clinical and Biological Markers of Ovarian Reserve (clinicaltrials.gov) - May 12, 2013
P=N/A, N=19, Terminated, Sponsor: Assistance Publique - H
N=50 --> 24 Recruiting --> Terminated; problems of insuffisant recruitment
- Enrollment change: IROCHIM: Evaluation of Chemotherapy Influence on Clinical and Biological Markers of Ovarian Reserve (clinicaltrials.gov) - May 12, 2013
P=N/A, N=19, Terminated, Sponsor: Assistance Publique - H
Recruiting --> Terminated; problems of insuffisant recruitment N=126 --> 19
- ||||| Enrollment change: Chemotherapy With or Without Additional Chemotherapy and/or Radiation Therapy in Treating Children With Newly Diagnosed Hodgkin's Disease (clinicaltrials.gov) - May 12, 2013
P3, N=1734, Active, not recruiting, Sponsor: Children's Oncology Group
N=126 --> 19 N=1000 --> 1734
- | bortezomib / Generic mfg., dexamethasone injection / Generic mfg., doxorubicin hydrochloride / Generic mfg.
New P2 trial: A Study of PAD Followed by Autologous Stem Cell Transplantation (ASCT) to Treat Newly Diagnosed Multiple Myeloma (clinicaltrials.gov) - May 12, 2013
P2, N=72, Recruiting, Sponsor: Shanghai Changzheng Hospital
- Trial termination: Stage I/II Nasal NK Cell Lymphoma (clinicaltrials.gov) - May 9, 2013
P1/2, N=1, Terminated, Sponsor: M.D. Anderson Cancer Center
N=1000 --> 1734 Recruiting --> Terminated; Slow Accrual
- Enrollment change: Stage I/II Nasal NK Cell Lymphoma (clinicaltrials.gov) - May 9, 2013
P1/2, N=1, Terminated, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Terminated; Slow Accrual N=40 --> 1
- || Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
New P3 trial: R-CEOP-90/R-CEOP-70 Versus R-CHOP-50 in the Treatment of Diffuse Large B-cell Lymphoma and Follicular Lymphoma Grade 3B (clinicaltrials.gov) - May 9, 2013
P3, N=600, Recruiting, Sponsor: Ruijin Hospital
- | cyclophosphamide / Generic mfg.
Enrollment closed: IBCSG 22-00: Low-dose Oral Cyclophosphamide and Methotrexate Maintenance for Hormone Receptor-negative Early Breast Cancer (clinicaltrials.gov) - May 9, 2013
P3, N=1080, Active, not recruiting, Sponsor: International Breast Cancer Study Group
N=40 --> 1 Recruiting --> Active, not recruiting
- || cyclophosphamide / Generic mfg., doxorubicin hydrochloride / Generic mfg., epirubicin / Generic mfg.
Trial completion: Efficacy and Safety of DLBS1425 as Neoadjuvant in Stage II or III Breast Cancer Patients (clinicaltrials.gov) - May 9, 2013
P2/3, N=40, Completed, Sponsor: Dexa Medica Group
Recruiting --> Active, not recruiting Recruiting --> Completed
- Decadron (dexamethasone) / Merck (MSD)
New P2 trial: Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Myeloma (clinicaltrials.gov) - May 7, 2013
P2, N=41, Recruiting, Sponsor: University of Iowa
- sildenafil / Generic mfg., doxorubicin hydrochloride / Generic mfg.
Enrollment change: Doxorubicin With or Without Sildenafil, With Analysis of Cardiac Markers (clinicaltrials.gov) - May 6, 2013
P1, N=50, Suspended, Sponsor: Virginia Commonwealth University
Recruiting --> Completed N=20 --> 50
- cyclophosphamide / Generic mfg., doxorubicin hydrochloride / Generic mfg.
Enrollment change: Dexamethasone and Ondansetron Hydrochloride or Palonosetron Hydrochloride in Preventing Nausea and Vomiting in Patients Receiving Doxorubicin Hydrochloride and Cyclophosphamide For Early Stage Breast Cancer (clinicaltrials.gov) - May 6, 2013
P=N/A, N=41, Completed, Sponsor: University of Washington
N=20 --> 50 N=57 --> 41
- imatinib / Generic mfg.
Trial initiation date: AALL01P2: Combination Chemotherapy and Imatinib Mesylate in Treating Children With Relapsed Acute Lymphoblastic Leukemia (clinicaltrials.gov) - May 5, 2013
P=N/A, N=126, Completed, Sponsor: National Cancer Institute (NCI)
N=57 --> 41 Initiation date: Sep 2001 --> Jan 2003
- | Rituxan (rituximab) / Roche
New P2 trial: BRCAP-GELTAMO12: Efficacy/Safety Study of R-CHOP vs Bortezomib-R-CAP for Young Patients With Diffuse Large B-cell Lymphoma With Poor IPI. (clinicaltrials.gov) - May 5, 2013
P2, N=127, Recruiting, Sponsor: Grupo Espa
- Beleodaq (belinostat) / Aurobindo, Spectrum Pharma
Enrollment open: Phase 1 Dose Finding Study of Belinostat for Treatment of Patients With Peripheral T-cell Lymphoma (PTCL) (clinicaltrials.gov) - May 5, 2013
P1, N=28, Recruiting, Sponsor: Spectrum Pharmaceuticals, Inc
Initiation date: Sep 2001 --> Jan 2003 Not yet recruiting --> Recruiting
- New P2 trial: Study of Propranolol in Newly Diagnosed Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy (clinicaltrials.gov) - May 2, 2013
P2, N=20, Recruiting, Sponsor: Columbia University
- Adcetris (brentuximab vedotin) / Takeda, Pfizer
Enrollment change: A Phase 1 Study of Brentuximab Vedotin Given Sequentially and Combined With Multi-Agent Chemotherapy for CD30-Positive Mature T-Cell and NK-Cell Neoplasms (clinicaltrials.gov) - Apr 30, 2013
P1, N=39, Active, not recruiting, Sponsor: Seattle Genetics, Inc.
Not yet recruiting --> Recruiting N=52 --> 39
- |||||| Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche, Rituxan Hycela (rituximab/hyaluronidase) / Biogen, Roche, Halozyme
Enrollment open, Combination therapy: A Study of Subcutaneous Versus Intravenous MabThera/Rituxan (Rituximab) in Combination With CHOP Chemotherapy in Patients With Previously Untreated CD20-Positive Diffuse Large B-Cell Lymphoma (clinicaltrials.gov) - Apr 27, 2013
P3, N=600, Recruiting, Sponsor: Hoffmann-La Roche
N=52 --> 39 Ongoing --> Recruiting
- Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Trial completion: Chemotherapy and Rituximab With or Without Total-Body Irradiation and Peripheral Stem Cell Transplant in Treating Patients With Lymphoma (clinicaltrials.gov) - Apr 25, 2013
P2, N=98, Completed, Sponsor: Memorial Sloan-Kettering Cancer Center
Ongoing --> Recruiting Active, not recruiting --> Completed
- | doxorubicin hydrochloride / Generic mfg., sorafenib / Generic mfg.
New P2 trial, Metastases: Sorafenib Plus Doxorubicin in Patients With Advanced Hepatocellular Carcinoma With Disease Progression on Sorafenib (clinicaltrials.gov) - Apr 23, 2013
P2, N=30, Recruiting, Sponsor: Memorial Sloan-Kettering Cancer Center
- | Beleodaq (belinostat) / Aurobindo, Spectrum Pharma
New P1 trial: Phase 1 Dose Finding Study of Belinostat for Treatment of Patients With Peripheral T-cell Lymphoma (PTCL) (clinicaltrials.gov) - Apr 22, 2013
P1, N=28, Recruiting, Sponsor: Spectrum Pharmaceuticals, Inc
- | doxorubicin hydrochloride / Generic mfg., sorafenib / Generic mfg.
Enrollment open, Metastases: Sorafenib Plus Doxorubicin in Patients With Advanced Hepatocellular Carcinoma With Disease Progression on Sorafenib (clinicaltrials.gov) - Apr 22, 2013
P2, N=30, Recruiting, Sponsor: Memorial Sloan-Kettering Cancer Center
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- | Trial completion: Treatment of Acute Lymphoblastic Leukemia in Children (clinicaltrials.gov) - Apr 22, 2013
P3, N=498, Completed, Sponsor: Dana-Farber Cancer Institute
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Enrollment change: Intensive Chemotherapy and Rituximab in the Treatment of Burkitt Lymphoma (clinicaltrials.gov) - Apr 16, 2013
P2, N=10, Terminated, Sponsor: Dana-Farber Cancer Institute
Active, not recruiting --> Completed N=30 --> 10
- | Trial completion: Comparison of Two Combination Chemotherapy Regimens in Treating Adults With Previously Untreated Leukemia or Lymphoma (clinicaltrials.gov) - Apr 16, 2013
P3, N=170, Completed, Sponsor: Memorial Sloan-Kettering Cancer Center
N=30 --> 10 Active, not recruiting --> Completed
- doxorubicin hydrochloride / Generic mfg.
Trial completion: Comparison Study of Transarterial Chemoembolization and Percutaneous Ethanol Injection for Multiple, Small HCCs (clinicaltrials.gov) - Apr 15, 2013
P3, N=22, Completed, Sponsor: Seoul National University Hospital
Active, not recruiting --> Completed Active, not recruiting --> Completed
- doxorubicin hydrochloride / Generic mfg.
Trial completion: Keyhole Limpet Hemocyanin Compared With Doxorubicin in Treating Patients With Bladder Cancer (clinicaltrials.gov) - Apr 15, 2013
P3, N=0, Completed, Sponsor: Intracel
Active, not recruiting --> Completed Suspended --> Completed
- | Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
New P1 trial: Feasibility of Assessing Lymphoma Response to Precise Local Injection of Candidate Chemotherapy Agents (clinicaltrials.gov) - Apr 11, 2013
P1, N=12, Recruiting, Sponsor: Presage Biosciences
- Leukine (sargramostim) / Partner Therap
Trial termination, Metastases: Combination Chemotherapy Plus Sargramostim in Treating Patients With Cancer of the Uterus (clinicaltrials.gov) - Apr 9, 2013
P2, N=0, Terminated, Sponsor: Gynecologic Oncology Group
Suspended --> Completed Completed --> Terminated
- Trial termination, Metastases: Combination Chemotherapy Compared With Hormone Therapy in Treating Patients With Recurrent, Stage III, or Stage IV Endometrial Cancer (clinicaltrials.gov) - Apr 9, 2013
P3, N=0, Terminated, Sponsor: Gynecologic Oncology Group
Completed --> Terminated Completed --> Terminated
- ||| GSK2302024A / GSK
Enrollment change: INDUCT: Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer (clinicaltrials.gov) - Apr 4, 2013
P2, N=250, Recruiting, Sponsor: GlaxoSmithKline
Completed --> Terminated N=180 --> 250
- ||||| Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
New P2 trial: A Study of VELCADE, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma (clinicaltrials.gov) - Apr 4, 2013
P2, N=164, Completed, Sponsor: Janssen Research & Development, LLC
- pantoprazole / Generic mfg., doxorubicin hydrochloride / Generic mfg.
Enrollment closed, Combination therapy, Metastases: Pantoprazole With Doxorubicin for Advanced Cancer Patients With Extension Cohort of Patients With Solid Tumours (clinicaltrials.gov) - Apr 2, 2013
P1, N=24, Active, not recruiting, Sponsor: University Health Network, Toronto
N=180 --> 250 Recruiting --> Active, not recruiting
- || albumin-bound paclitaxel / Generic mfg.
New P3 trial: ETNA: Neoadjuvant Chemotherapy With Nab-paclitaxel in Women With HER2-negative High-risk Breast Cancer (clinicaltrials.gov) - Mar 31, 2013
P3, N=632, Recruiting, Sponsor: Fondazione Michelangelo
- Avastin (bevacizumab) / Roche
Enrollment open: Bevacizumab/Doxorubicin/Radiation for Sarcoma (clinicaltrials.gov) - Mar 28, 2013
P1, N=18, Recruiting, Sponsor: Massachusetts General Hospital
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- cyclophosphamide / Generic mfg., docetaxel / Generic mfg.
Trial termination: NATT: Neoadjuvant Treatment of Docetaxel, Anthracycline and Cyclophosphamide (TAC) Versus Docetaxel and Cyclophosphamide (TC) in Triple-Negative or Her2 Positive Breast Cancer (clinicaltrials.gov) - Mar 26, 2013
P3, N=102, Terminated, Sponsor: Shanghai Jiao Tong University School of Medicine
Not yet recruiting --> Recruiting Recruiting --> Terminated; TAC treatment was associated with better survial outcome compared with TC treatment, we terminated recruiting and waiting for longer follow up period.
- cyclophosphamide / Generic mfg., docetaxel / Generic mfg.
Enrollment change: NATT: Neoadjuvant Treatment of Docetaxel, Anthracycline and Cyclophosphamide (TAC) Versus Docetaxel and Cyclophosphamide (TC) in Triple-Negative or Her2 Positive Breast Cancer (clinicaltrials.gov) - Mar 26, 2013
P3, N=102, Terminated, Sponsor: Shanghai Jiao Tong University School of Medicine
Recruiting --> Terminated; TAC treatment was associated with better survial outcome compared with TC treatment, we terminated recruiting and waiting for longer follow up period. N=600 --> 102
- Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
New P2 trial: Trial of DA-EPOCH Regimen for NHL With HLH (clinicaltrials.gov) - Mar 25, 2013
P2, N=50, Recruiting, Sponsor: Jiangsu Province Hospital
- Poteligeo (mogamulizumab) / Kyowa Kirin
Trial completion: Multicenter, Randomized, Open-label, Parallel-group Study to Compare mLSG15 + KW-0761 to mLSG15 (clinicaltrials.gov) - Mar 25, 2013
P2, N=0, Completed, Sponsor: Kyowa Hakko Kirin Company, Limited
N=600 --> 102 Active, not recruiting --> Completed
- |||| Kinenza (enzastaurin) / Denovo, Aytu BioPharma, Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Trial completion: A Study of Participants With Lymphoma Who Take R-CHOP and Enzastaurin Compared to Participants Who Take R-CHOP Only (clinicaltrials.gov) - Mar 25, 2013
P2, N=100, Completed, Sponsor: Eli Lilly and Company
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Avastin (bevacizumab) / Roche
Trial completion: Preoperative Dose-dense Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Bevacizumab in Operable Breast Cancer (clinicaltrials.gov) - Mar 21, 2013
P2, N=104, Completed, Sponsor: Ian E. Krop, MD, PhD
Active, not recruiting --> Completed Recruiting --> Completed
- ||| cyclophosphamide / Generic mfg., doxorubicin hydrochloride / Generic mfg., docetaxel / Generic mfg.
Enrollment closed, Metastases: NeoSAMBA: Neoadjuvant: Does the Sequence of Anthracycline and Taxane Matters: Before or After? (clinicaltrials.gov) - Mar 17, 2013
P2, N=112, Active, not recruiting, Sponsor: Instituto Nacional de Cancer, Brazil
Recruiting --> Completed Recruiting --> Active, not recruiting
- alvocidib (DSP-2033) / Sumitomo Pharma
Trial completion, Surgery, Metastases: Doxorubicin Hydrochloride and Alvocidib in Treating Patients With Metastatic or Recurrent Sarcoma That Cannot Be Removed By Surgery (clinicaltrials.gov) - Mar 17, 2013
P1, N=36, Completed, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- || New P3 trial, Metastases: VESPER: Perioperative Chemotherapy for Patients With Locally Advanced Bladder Cancer (clinicaltrials.gov) - Mar 14, 2013
P3, N=500, Recruiting, Sponsor: University Hospital, Rouen
- || Asparlas (calaspargase pegol-mknl) / Servier, Takeda, Leadiant Biosci, Oncaspar liquid (pegaspargase) / Servier
Enrollment closed: AALL07P4: Calaspargase Pegol or Pegaspargase and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Mar 13, 2013
P=N/A, N=166, Active, not recruiting, Sponsor: Children's Oncology Group
Active, not recruiting --> Completed Suspended --> Active, not recruiting
- |||| Nplate (romiplostim) / Amgen, Kyowa Kirin
Trial completion, Metastases: AMG 531 in Patients With Advanced Malignancy Receiving Treatment With Carboplatin (clinicaltrials.gov) - Mar 12, 2013
P1/2, N=55, Completed, Sponsor: M.D. Anderson Cancer Center
Suspended --> Active, not recruiting Active, not recruiting --> Completed
- cisplatin / Generic mfg., doxorubicin hydrochloride / Generic mfg.
New P2 trial: Intraperitoneal Aerosol High-pressure Chemotherapy for Women With Recurrent Ovarian Cancer (clinicaltrials.gov) - Mar 10, 2013
P2, N=50, Recruiting, Sponsor: Ruhr University of Bochum